Steeped in Science.
Loved by Physicians.

RICH ALDRICH

Rich Aldrich is a Co-Founder and Partner of Longwood Fund. He has co-founded and helped to build several successful biotech companies including Sirtris Pharmaceuticals (NASDAQ: SIRT acquired by GlaxoSmithKline); Concert Pharmaceuticals (acquired by Sun Pharmaceuticals) where he served as Chair of the Board; and Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), Verastem (NASDAQ: VSTM), Axial Therapeutics, and TScan Therapeutics. Rich currently serves as a Director of Longwood portfolio companies Axial, Sitryx Therapeutics, and Colorescience.

Prior to co-founding Longwood, Rich founded RA Capital Management, LLC, a life sciences investment fund, in which he remains an investor. Prior to founding RA Capital Management, LLC, he was a founding employee of Vertex Pharmaceuticals (NASDAQ: VRTX) where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to Vertex, he held several management positions at Biogen Inc.

Rich received his undergraduate degree from Boston College and an MBA from the Amos Tuck School at Dartmouth College.

MARY FISHER

Mary is the Chair and Chief Executive Officer at Colorescience, a former division of SkinMedica Inc. where she served as Chief Executive Officer from 2008 until 2012. She led the successful sale of the company to Allergan, Inc. for $350 million with the potential for another $25 million contingent on certain sales milestones.

Mary has spent more than 30 years in the pharmaceutical and biotechnology industries, including management and leadership positions at Acorda Therapeutics, Cephalon, Immunex and Boehringer Ingelheim. She also serves on the board of directors of Dermata Therapeutics.

Mary was honored as Ernst & Young's Entrepreneur of the Year for San Diego, California, and received the EY Venture Capital Award of Excellence. She was also recently named a finalist for Most Admired CEO by the San Diego Business Journal.

NICKY KINNAIRD

Nicky Kinnaird is a long-time, esteemed innovator in the beauty industry. She revolutionized retail beauty in the early 1990’s with the launch of Space NK Apothecary in London’s Covent Garden. The ground-breaking boutique featured a curated mix of beauty and wellbeing lines and quickly grew into an international beauty mecca—known for offering consumers a unique selection of the finest established and burgeoning brands. Having stepped down from her Space NK duties over 2 years ago, Kinnaird has fed her passion for the evolution of consumer-focused beauty by consulting on growing brands.

ADELE OLIVA

Adele Oliva brings decades of finance and healthcare experience to 1315 Capital, including 20 years in private equity focused on commercial stage specialty pharmaceutical, medical technology, and healthcare service investments.

Adele co-founded 1315 Capital in 2015 to establish a firm focused on healthcare growth investing. She was recruited to Quaker Partners in 2007 to expand their growth stage investing practice. Prior to Quaker, Adele was Co-Head of US Healthcare at Apax Partners, where she started in 1997.

Forbes recognized Adele on its Midas List of top 100 technology investors worldwide, top 10 life science investors and top women in venture capital.

Adele has served on the board of Ascent Healthcare Solutions (acquired by Stryker), EKR Therapeutics (acquired by Cornerstone Therapeutics), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Precision Dermatology (acquired by Valeant), Prometheus Labs (acquired by Nestle) and SkinMedica (acquired by Allergan). She currently serves on the boards of Colorescience, Genoptix, Innovative Health, NovaSom, Onkos Surgical, and TELA Bio.

Prior to entering private equity as a Kauffman Fellow, Adele held roles at CoreStates in commercial banking and Baxter Healthcare in marketing and business development.

Adele received a BSc from St. Joseph’s University and an MBA from Cornell University, where she was awarded the Albert Fried Fellowship.

DAVID OLSEN

David Olsen is a Managing Director at Highlander Partners. He leads the company’s efforts in sourcing investments in the beauty and personal care industry and plays an integral strategic role in these businesses post-close. He also works closely with Highlander’s existing CPG-oriented businesses in the areas of product development, branding and channel expansion with an emphasis on digital excellence. David has been a leader in the digital retail space for 20 years.

Since 2016, and just prior to joining Highlander, he served as the CEO of private equity backed Cos Bar, where he brought his digital and ecommerce expertise to transition and grow a traditionally brick-and-mortar beauty retailer into an omni-channel business, while remaining true to its luxury DNA. Prior to Cos Bar, he launched the beauty and grooming businesses at Net-A-Porter and Mr. Porter as Global Vice President, growing those businesses by triple digits annually during his tenure. He originally founded and was the CEO of an e-commerce cosmeceutical business, DermTeam, which he later sold to DermStore, where he went on to lead business development, buying, and operations before selling the business to Target in 2012